Role of angiotensin II in the development of peripheral vasoconstriction during cardiopulmonary bypass.

The possible relationship between angiotensin II -- the end product of the renin-angiotensin system, and the increase in peripheral vasoconstriction associated with cardiopulmonary bypass, has been investigated in 12 patients undergoing elective open-heart surgical procedures. Plasma angiotensin II (AII) levels were measured by radio-immunoassay at the start and the end of the period of cardiopulmonary bypass. Measurements of peripheral vascular resistance index were made at the times of AII sampling. Plasma AII levels rose during CPB from 78.0 to 231.3 pg.cm-3 (normal values less than 35 pg.cm-3). Peripheral vascular resistance index also rose during perfusion from 20.87 to 27.83 units. The rise in plasma AII levels and in peripheral vascular resistance index were correlated for each of the 12 patients. A highly significant correlation was obtained (r = 0.91; P less than 0.001). These results confirm the presence of parallel rises in plasma angiotensin II levels and in peripheral vasoconstriction during conventional non-pulsatile cardiopulmonary bypass, and suggest that increased plasma AII levels may be principal causative factor in the increased vasoconstriction associated with open-heart surgical procedures.

Anterior pituitary response to thyrotrophin-releasing hormone during open-heart surgery.

The anterior pituitary response to thyrotrophin-releasing hormone has been studied in 20 patients submitted to elective open-heart surgical procedures, and in six control patients submitted to closed mitral valvotomy. Standard non-pulsatile normothermic perfusion was used in all the open-heart cases. 400 microgram thyrotropin-releasing hormone was administered by intravenous injection during bypass, at 30 min post-bypass, and at 60 min post-bypass. The same dose (400 microgram) was given during closed mitral valvotomy (Control Group). Thyrotrophin-releasing hormone administration during bypass failed to produce a normal response from the anterior pituitary, in contrast to the normal response pattern seen in the control group (P less than 0.01). Thyrotrophin-releasing hormone given after the period of bypass produced responses within the normal range in the majority of patients. These results suggest that anterior pituitary hypofunction may exist during the period of extracorporeal circulation using non-pulsatile perfusion and that recovery of pituitary function is evident within the first hour post-extracorporeal circulation.

Radiographic appearances of implanted transvenous endocardial pacing electrodes.

It is important to ensure correct positioning of long-term pacing electrodes. Electrocardiograms and the radiographic appearance of pacing electrodes are conventionally used to confirm the site of the pacing electrode. Electrocardiographic patterns from stimulation of the right ventricle and left ventricle of the heart through the coronary venous system and the limitations in the interpretations of these patterns have been well documented in the past. The appearances of chest x-ray films can also be misleading. In the present study performed on cadavers, detailed appearances of pacing electrodes placed electively in different sites in the right ventricle and in the coronary sinus and its radicles are described, and the limitations in the interpretations of such appearances are discussed.

Björk-Shiley and Carpentier-Edwards valves. A comparative analysis.

Between January 1977 and December 1982, 986 Björk-Shiley and 744 Carpentier-Edwards valves were implanted in 774 and 620 patients, respectively, at the same institution. All Björk-Shiley patients and 57% of patients with a Carpentier-Edwards valve in the mitral position received long-term anticoagulation. Mean follow-up was 3.2 years (range 0 to 8.8) in the Björk-Shiley patients and 3.5 years (range 0 to 8.2) in the Carpentier-Edwards group. There was no significant difference between the two groups in hospital mortality (Björk-Shiley 7.6%; Carpentier-Edwards 6.0%), overall incidence of embolism (Björk-Shiley 1.4 per 100 patient-years; Carpentier-Edwards 1.6% py), endocarditis (Björk-Shiley 0.6% py; Carpentier-Edwards 0.8% py), periporsthetic leak (Björk-Shiley 1.6% py; Carpentier-Edwards 1.4% py), anticoagulant-related complications (Björk-Shiley 0.3% py; Carpentier-Edwards 0.1% py), valve failure (Björk-Shiley 0.78% py; Carpentier-Edwards 0.68% py), reoperation for complication (Björk-Shiley 1.68% py; Carpentier-Edwards 1.22% py), and late mortality (Björk-Shiley 3.1% py; Carpentier-Edwards 3.0% py). Actuarial freedom from valve-related events was similar in the two groups. In the aortic position, freedom from embolism was significantly better in the Björk-Shiley group than the Carpentier-Edwards group (Björk-Shiley 99% at 3 and 5 years; Carpentier-Edwards 96% and 92% at 3 and 5 years; p = 0.023). In the mitral position, the overall incidence of reoperation was higher in the Björk-Shiley group (1.78% py) than in the Carpentier-Edwards group (0.48% py) (p = 0.004). Actuarial analysis shows this difference to be confined to the first 6 years of follow-up. The commonest indication for reoperation was valve failure in both groups. However, when analysis is confined to this indication, the difference between the reoperation incidence in the mitral position becomes insignificant (Björk-Shiley 0.85% py; Carpentier-Edwards 0.29% py; p = 0.085). This study confirms the satisfactory performance of both the Carpentier-Edwards and Björk-Shiley valves in the short and middle term and indicates no clear-cut advantage for either prosthesis.

Comparative studies of pulsatile and nonpulsatile flow during cardiopulmonary bypass. III. Response of anterior pituitary gland to thyrotropin-releasing hormone.

Previous studies have indicated that, during nonpulsatile cardiopulmonary bypass, the anterior pituitary gland fails to respond to the tropic stimulus of thyrotropin-releasing hormone (TRH). This is in contrast to the normal response seen during closed cardiac and general surgical procedures. The Stöckert pulsatile pump system described in Part I has been employed in a comparative study of TRH responses in 20 patients subjected to pulsatile or nonpulsatile perfusion during open-heart surgery. In the nonpulsatile group, a consistently subnormal response to TRH injection was again found. In the pulsatile group, however, the pituitary response to TRH was normal in nine patients out of 10. The quantitative difference between the groups was statistically highly significant (p less than 0.005). These results indicate that the subnormal pituitary function seen with nonpulsatile bypass may be prevented by the use of pulsatile perfusion.

The effect of hemodilution on plasma levels of cortisol and free cortisol.

The effect of hemodilution on plasma levels of total cortisol and free cortisol was studied in 12 patients undergoing open-heart surgery. In each case, at the onset of extracorporeal circulation (ECC) the hematocrit value was rapidly reduced to 25 to 30 per cent and was maintained around this level during perfusion. Total plasma cortisol levels fell significantly with the hemodilution (p less than 0.0001), but the plasma concentration of free, biologically active cortisol was maintained at its pre-dilution level because of an increase in the percentage of plasma cortisol existing in the free form. There was a highly significant correlation between the degree of hemodilution and the percentage rise in the free cortisol fraction (r = 0.79; p less than 0.001). These results indicate the presence of a compensatory mechanism associated with cortisol binding which maintains the plasma level of free, biologically active cortisol when hemodilution has reduced the plasma level of total cortisol.

Fourteen years' experience with the Björk-Shiley tilting disc prosthesis.

Between 1970 and 1984, 1,574 Björk-Shiley valve prostheses have been implanted in 1,171 patients in Glasgow. Between 1970 and 1980, 1,023 standard disc prostheses were implanted in 729 patients: 184 had aortic valve replacement, 323 mitral, and 222 multiple valve replacement. Between 1980 and 1984, 551 convexo-concave valves were implanted in 442 patients: 125 had aortic, 228 mitral, and 89 multiple valve replacement. Concomitant coronary artery bypass grafting was performed in 9.2% of the latter group as compared with 2.7% of the earlier group. The overall hospital (30 day) mortality for the group with the standard disc prosthesis was 10.4% and for patients with the convexo-concave prosthesis, 7.0%. Cumulative follow-up extends to 4,125 patient-years--standard disc group 3,378 patients-years, range 4 to 14 years (mean 5.2 years); convexo-concave group 747 patient-years, range 1.5 to 5.3 years (mean 1.9 years). The late mortality is 3.8% per patient-year--standard disc group 2.9% per patient-year and convexo-concave group 4.3% per patient year (no significant difference). Actuarial survival rate at 12 years for the whole group, excluding operative deaths, is 69.4% +/- 6.3%. The freedom from all valve-related complications at 12 years is 65.9% +/- 6.5%. there is no significant difference in the incidence of most major complications between the standard disc and convexo-concave prostheses apart from the occurrence of mitral valve thrombosis (p less than 0.05) in the standard disc group and outlet strut fracture (p less than 0.005) in the convexo-concave group. These results confirm the excellent long-term performance of the Björk-Shiley tilting disc prosthesis.

Hypothalamo-pituitary-thyroid axis function during cardiopulmonary bypass.

Marked alterations in levels of circulating thyroid hormone were found in patients undergoing cardiopulmonary bypass with a rise in the free thyroxine and a fall in the free triiodothyronine levels. Studies using thyrotropin-releasing hormone during bypass demonstrated a blunted response to this stimulus. This reduced response is related to changes in thyroid hormone levels and it is suggested that bypass surgery may have a direct inhibitory action on thyroid-stimulating hormone release at the hypothalamo-pituitary level. The potential significance of these hormonal changes is discussed.

Comparative studies of pulsatile and nonpulsatile flow during cardiopulmonary bypass. I. Pulsatile system employed and its hematologic effects.

A new, commercially available roller pump system able to deliver pulsatile and nonpulsatile flow has been studied in patients undergoing elective open-heart surgical procedures. The pulsatile pump (Stöckert Instrumente) may be used with standard extracorporeal circuit equipment and consistently produces a peripheral arterial pulse pressure of 25 to 30 mm. Hg at mean flow rates of 3.5 to 4.0 L. per minute. Twenty patients, arbitrarily allocated to pulsatile or nonpulsatile groups, have been studied. There were no significant differences between the groups in respect of age, weight, bypass time, pump flow, or mean arterial pressure during bypass. Comparative studies of the hematologic effects of pulsatile and nonpulsatile perfusion were carried out. There was no evidence of increased hemolysis with pulsatile flow, nor was there increased depletion of red blood cells (RBC's) or platelets in the pulsatile group. This pulsatile pump system may therefore be used to produce pulsatile perfusion during cardiopulmonary bypass without the fear of producing excessive blood cell trauma.

Comparative studies of pulsatile and nonpulsatile flow during cardiopulmonary bypass. II. The effects on adrenal secretion of cortisol.

Previous studies have indicated that a significant reduction in plasma cortisol levels occurs during nonpulsatile cardiopulmonary bypass as a result of adrenocorticol hypofunction. The Stöckert pulsatile pump system described in Part I has been employed in a comparative study of plasma cortisol levels in 20 patients subjected to pulsatile or nonpulsatile perfusion during open-heart surgery. The plasma cortisol response pattern in the nonpulsatile group was identical to the pattern previously described, with no significant rise in cortisol levels during the period of perfusion. In the pulsatile group, however, plasma cortisol levels rose significantly during perfusion, reaching a mean level at the end of perfusion which was highly significantly greater than that in the nonpulsatile group (p less than 0.001). Correction of the plasma cortisol values for the effect of hemodilution was performed and, again, corrected cortisol values indicated a highly significant increase in end-bypass levels in the pulsatile groups (p less than 0.001). These results clearly indicate that the reduction in cortisol secretion during nonpulsatile bypass may be prevented by the use of pulsatile perfusion.

Heart valve replacement with the Björk-Shiley Monostrut valve: early results of a multicenter clinical investigation.

To evaluate the clinical performance of the Björk-Shiley Monostrut prosthesis, five centers combined their early experience. Between May, 1982, and June, 1985, 537 prostheses were implanted in 486 patients at these centers: 246 patients had aortic valve replacement (AVR), 163 underwent mitral valve replacement (MVR), and 47 had double-valve replacement (DVR). Thirty patients underwent other, more complex procedures. Concomitant cardiac procedures were performed in altogether 25%. Overall hospital (30 days) mortality was 5.1% (3.6% for AVR, 4.3% for MVR, 8.3% for DVR, and 16.6% for other procedures). The patients were followed up at 6- to 9-month intervals from 6 to 48 months (mean follow-up, 33 months). Follow-up was 99.6% complete. Late mortality was 7.2%. The three-year survival rate was 91.0% for AVR, 92.3% for MVR, and 76.2% for DVR. There was no structural failure of the prosthesis. No instances of valve thrombosis and fatal thromboembolism occurred in anticoagulated patients. The three-year incidence of freedom from thromboembolic events (including TIA) was 89.8% for AVR, 94.9% for MVR, and 90.2% for DVR. Preoperative and postoperative data for the assessment of mechanical hemolysis was available in 60% of the patients. The degree of mechanical hemolysis was low and did not change with time. Although the follow-up is still short, the Björk-Shiley Monostrut prosthesis appears to represent an improvement over previous Björk-Shiley models, particularly with regard to durability.

Experience in the development of low haemolysis pumps.

In an attempt to provide a pulsatile pump with a low rate of haemolysis, two pulsatile pumps have been developed. These were compared with commercially available pulsatile and roller pumps. The blood flow and the rate of haemolysis were studied under similar conditions. Our pumps were significantly better than the commercial pumps as far as mechanical damage to the red blood cells was concerned. However, we carried out certain modifications to one of our pumps which resulted in a significant reduction in the amount of haemolysis over its previous performance.

"Sore buttock syndrome": aseptic inflammation of the gluteal region following cardiopulmonary bypass.

Aseptic inflammation of the gluteal region is a not uncommon cause of early postoperative morbidity following open heart surgery in our patients. We believe that this condition may result from local ischaemia induced by pressure during the period of reduced perfusion on cardiopulmonary bypass. To date, this complication has not been described.

Follow-up after coronary revascularisation in patients with renal transplants.

Seven patients underwent coronary revascularisation 12-145 months (mean: 63.4 months) after receiving cadaver renal transplants. There was no operative mortality and in all patients satisfactory renal function was maintained perioperatively. Hospital stay ranged from 7 days to 10 days (mean: 8 days). During the period of follow-up (5-72 months, mean: 35 months): one patient remained angina-free at 7 months postoperatively; one patient developed meningitis with Listeria monocytogenes 9 weeks after surgery, and died of streptococcal septicaemia 11 weeks later. The other five patients (71.4%) developed recurrence of angina requiring antianginal therapy, and three of them sustained myocardial infarctions. Three patients developed intermittent claudication, two of whom sustained acute leg ischaemia. Two patients developed heart failure, one of whom died 38 months postoperatively. In four patients who were restudied with cardiac catheterisation and coronary angiography (2-17 months postoperatively) there was evidence of progression of the coronary arterial disease in three, although all coronary grafts were patent. Renal function remained satisfactory in 5 patients, and deteriorated in two patients; in one secondary to advanced heart failure; and in one as a terminal event secondary to septicaemia. Although patients with renal transplants can safely undergo open cardiac procedures, the long-term results of coronary surgery are adversely affected by the progressive disease from which they suffer.

Clinical evaluation of the Björk-Shiley disc valve in the tricuspid position. Long-term results.

Between 1971 and 1981, 1210 Björk-Shiley prostheses were implanted. Of these, 79 were in the tricuspid position, comprising 30 triple valve replacements, 46 mitral plus tricuspid, and 3 isolated tricuspid replacements. The ages ranged from 10-55 years (mean 45 years). Sixty-three patients (80%) were in NYHA grades III or IV preoperatively. Thirteen patients died in hospital after surgery (16.5%). The 66 survivors have been followed for up to 16 years (mean 7.5 years). There have been 37 late deaths (7.5 per patient year). Twelve were valve-related: 4 tricuspid complications, 4 mitral complications, 2 prosthetic endocarditis, 1 aortic leak and 1 anticoagulant-related bleed. Twenty-one late deaths were not valve-related, and 4 causes of death are unknown. Expressed actuarially, survival at 5 years was 68%, and at 10 years, 49.4% +/- 12%. Freedom from valve-related death at 10 years was 80.7% +/- 7%. At last follow-up, 90% of the survivors were in NYHA class 1 or 2 with only modest signs of venous hypertension. The commonest life-threatening complication was obstruction of the tricuspid prosthesis by tissue ingrowth. This occurred in 7 patients (1.4% per patient year) 4 were re-operated upon and survived, 3 died. Doppler echocardiography has been carried out on 27 survivors of whom 5 had abnormal pressure-half times but only 3 of these were symptomatic. This series shows that function of the standard disc Björk-Shiley prosthesis in the tricuspid position compares favourably with other prostheses. The problem of tissue ingrowth can be diagnosed by echo Doppler and reoperation successfully carried out.

Mechanical versus biological heart valves: a ten-year comparison in a single centre.

Between January 1977 and December 1986, 1606 Bjørk-Shiley tilting disc prostheses (BS) and 1346 Carpentier Edwards porcine prostheses (CE) were implanted in 1300 and 1156 patients, respectively, at the same institution. During the time of implantation, both valves have developed: the BS through standard disc and convexo-concave to monostrut, and the CE valves from standard to supra-annular. Newer valve types were used where applicable as they became available. Preoperative status in respect of age and cardiac rhythm were similar. There were significantly more females (64% BS: 54% CE, P less than 0.001); worse NYHA grade (74% Grade 111 and IV-BS: 56% 111 and IV-CE, P less than 0.001) more closed heart surgery (26% BS: 18% CE, P less than 0.001) and more previous open heart surgery (11.6% BS: 8.9% CE, P less than 0.001) in the BS group. All BS patients were anticoagulated and 49% of mitral CE patients and 7% of aortic CE patients were anticoagulated. There was no significant difference between the two groups in hospital mortality (BS 7.2%: CE 6.3%), late mortality (BS 2.5%/patient year: CE 3.2%/patient year) overall incidence of systemic embolism (BS 1.3%/patient year: CE 1.4/patient year), prosthetic valve endocarditis (BS 0.7%/patient year: CE 0.9%/patient year), valve failure (BS 0.5%/patient year: CE 0.9%/patient year) or peri-prosthetic leak (BS 1.2%/patient year: CE 1.3%/patient year). The incidence of systemic embolism in the aortic position was lower with the BS prosthesis (BS 0.2%/patient year: CE 1.2%/patient year, P less than 0.02).(ABSTRACT TRUNCATED AT 250 WORDS)

Endogenous digoxin-like immunoreactive substance in patients undergoing coronary surgery. Preliminary report.

Perioperative digoxin concentrations were measured in 20 unselected adult patients undergoing coronary surgery. None of the patients were receiving treatment with digoxin. A digoxin-like immunoreactive substance was found in 16 patients postoperatively. This substance, if pharmacologically active, may have important clinical implications in the management of patients after open heart surgery.

Sinoatrial disorders, the "sick sinus" syndrome. Experience with implanted cardiac pacemakers.

The long term results of permanent pacemaker implantation in patients with disorders of the sinoatrial node and atrial conduction pathways were studied. In a consecutive series of 300 patients treated by pacemaker implantation, 68 ((22.3%) had sinoatrial disorders. Mean age of the group was 54 years (33-82 years); 37 were male, 31 female. Diagnosis was confirmed by serial electrocardiography with overdrive suppression of sinoatrial node function as indicated. Twenty-two patients presented with sinus bradycardia alone (Type I disorder) and 46 with bradycardia-tachycardia syndrome (Type II disorder) were completely controlled. of the 46 Type II patients, in 30 (65.2%) tachyarrhythmias were controlled by pacing alone and in 14 (30.4%) by pacing and antiarrhythmic drug therapy. Congestive cardiac failure was relieved in 80% and anginal pain in 70% of patients with rate control alone. Systemic embolisation did not recur after pacemaker implantation. The average duration of pacemaker therapy was 52 months (12-96 months). In this series, long term ventricular demand pacing proved beneficial in both types of sinoatrial disorders.

Early systemic hypertension after surgical closure of atrial septal defect.

The systemic haemodynamic changes occurring in the immediate post-operative period were examined in a series of patients undergoing closure of atrial septal defect (A.S.D.) and in a consecutive series of all patients undergoing open-heart surgery in this Unit. Significant systemic hypertension was observed in 47.5% of patients in the A.S.D. series. In an attempt to explain this finding, several other haemodynamic variables were examined in relation to the systemic blood pressure. There was no correlation between central venous pressure or blood loss and systemic blood pressure. However, there was an inverse correlation between blood balance and systolic and diastolic blood pressure at 4 hours after operation. The explantation of this finding is unclear but it may be due to the effects on atrial receptors of lower right atrial and pulmonary artery pressures following closure of the A.S.D. Although the post-operative systemic hypertension was transient in most cases, it may produce adverse effects in the early post-operative period and therefore treatment with hypotensive agents should be considered in severe cases.

Hypernatraemic dehydration following tricuspid valve replacement.

The development of abnormally high plasma sodium and plasma osmolality levels is described in 5 patients following open-heart surgery involving prosthetic replacement of the tricuspid valve. These biochemical abnormalities developed in the early post-operative period and were associated with an excessive diuresis during the first 3 to 4 days after operation. Biochemical correction required a prolonged, high volume intravenous water load, and was paralleled by progressive clinical improvement, notably in peripheral circulation, tissue turgor and cerebral function. Plasma sodium and osmolality levels and observed fluid balance in 20 patients undergoing similar surgical procedures for tricuspid valve lesions fail to show this hypernatraemic, hyperosmolar state, and indicate that the majority of such patients have a markedly positive observed fluid balance in the early post-operative period. These differences are statistically highly significant (p less than 0.001). Consideration of urine/plasma osmolality levels reveals a transient but highly significant impairment of renal concentration in the hypernatraemic patients (p less than 0.001).